IL6R and prostate adenocarcinoma: We utilized two in vivo models that express CD126 for tumor control (MM and prostate adenocarcinoma), and in both scenarios, the CAR-T cells infiltrated the tumor xenografts, were activated, expanded, and led to tumor cytoreduction.